Chronic hepatitis B virus (HBV) infection affects about 296 million people worldwide and is
the leading aetiology of cirrhosis and liver cancer globally. Major medical complications also …

Nucleos (t) ide analogues (NA) are widely used to treat hepatitis B virus (HBV) infection, but
they cannot eradicate the virus and treatment duration can be lifelong if the endpoint is set at …

Background Finite nucleos (t) ide analogue (NUC) therapy has been proposed as an
alternative treatment strategy for chronic hepatitis B (CHB). Aim To quantify the incidence of …

The majority of chronic viral hepatitis cases are induced via infection with the hepatitis B
virus (HBV), hepatitis C virus (HCV), or hepatitis D virus (HDV). These patients are at …

Background & Aims Antivirals represent the mainstay of chronic hepatitis B treatment given
their efficacy and tolerability, but rates of functional cure remain low during long-term …

In recent decades, microRNAs (miRNAs) have emerged as key regulators of gene
expression, and the identification of viral miRNAs (v-miRNAs) within some viruses, including …

ABSTRACT Introduction Chronic hepatitis B (CHB) infection is a major global health threat
and accounts for significant liver-related morbidity and mortality. An improved understanding …

Objective Several risk prediction algorithms have been developed to guide antiviral therapy
initiation among patients with chronic hepatitis B (CHB). This study assessed the cost …

Introduction Nucleos (t) ide analogues (NAs) are effective in suppressing the replication of
the hepatitis B virus. However, NAs cannot effectively induce hepatitis B surface antigen …

Background HBeAg loss is an important endpoint for antiviral therapy in chronic hepatitis B
(CHB), however there are no reliable biomarkers to identify patients who will respond to the …